GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study
Open Access
- 28 April 2005
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 20 (6), 1516-1520
- https://doi.org/10.1093/humrep/deh832
Abstract
BACKGROUND: The specific role of LH in folliculogenesis and oocyte maturation is unclear. GnRH antagonists, when administered in the late follicular phase, induce a sharp decrease in serum LH which may be detrimental for IVF outcome. This study was performed to evaluate whether the replacement of GnRH agonist (triptorelin) by a GnRH antagonist (ganirelix; NV Organon) in oocyte donation cycles has any impact on pregnancy and implantation rates. METHODS: A total of 148 donor IVF cycles was randomly assigned to use either a GnRH antagonist daily administered from the 8th day of stimulation (group I) or a GnRH agonist long protocol (group II) for the ovarian stimulation of their donors. The primary endpoints were the pregnancy and the implantation rates. RESULTS: The clinical pregnancy rate per transfer (39.72%, 29/73 versus 41.33%, 31/75) based on transvaginal scan findings at 7 weeks of gestation, the implantation rate (23.9 versus 25.4%) and the first trimester abortion rate (10.34 versus 12.90%) were similar in the two groups. CONCLUSION: In oocyte donation cycles the replacement of GnRH agonist by a GnRH antagonist appears to have no impact on the pregnancy and implantation rates when its administration starts on day 8 of stimulation.Keywords
This publication has 23 references indexed in Scilit:
- Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cyclesFertility and Sterility, 2004
- Coasting acts through downregulation of VEGF gene expression and protein secretionHuman Reproduction, 2004
- Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancyFertility and Sterility, 2003
- GnRH antagonist in assisted reproduction: a Cochrane reviewHuman Reproduction, 2002
- Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulationHuman Reproduction, 2001
- Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trialHuman Reproduction, 2000
- Embryo implantation and GnRH antagonistsHuman Reproduction, 2000
- Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonists and antagonistsHuman Reproduction, 1999
- EndocrinologyHormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix)Human Reproduction, 1996
- Ovarian Hyperstimulation SyndromeObstetrical & Gynecological Survey, 1989